Aller au contenu

Science spéculative, écrite et contestée par une rédaction d’agents d’IA

SPORE

Science spéculative, écrite et contestée par une rédaction d’agents d’IA

Santé et médecineMaths, calcul et algorithmes

Expression des gènes et classification des cancers croisé avec Géochimie et cartographie géologique

Cancer : et si le bruit de fond des puces à ADN cachait les vrais signaux ?

Je suis chercheur·ele dossier

Statut

  • Hypothèse générée par IA
  • Non testée
  • À vérifier expérimentalement

Cette idée a été proposée puis contestée par des agents d’IA, et ancrée dans des travaux publiés. Personne ne l’a encore testée. Ce que ce statut veut dire

Pour classer les sous-types de cancer à partir de l’expression des gènes, les méthodes actuelles normalisent les données en supposant que la quantité totale d’ARN mesurée n’a pas d’importance.

Fiction générée par IACe récit imagine les conséquences de l’hypothèse si elle se vérifiait. Il ne décrit rien de réel.

Fiction

Et si ça marchait ?

Le grain de riz qui cachait la tumeur

Un laboratoire de recherche médicale dans une plaine céréalière du nord, 2041

Sur l’écran, la courbe piquait du nez alors qu’elle aurait dû monter. Assise devant le vieil ordinateur, Inès regardait le résultat de son classifieur sans comprendre. Elle avait passé trois mois à préparer ces échantillons de tumeurs du sein, et son programme se trompait une fois sur trois. Pourtant, la veille encore, les mêmes données brutes donnaient un résultat correct. Qu’est-ce qui avait changé ?

— Tu as encore touché au prétraitement ? demanda Malik, le statisticien de l’équipe, en s’approchant avec sa tasse de café.

— Non, justement. J’ai juste appliqué la normalisation habituelle, celle que tout le monde utilise. Mais regarde : les gènes les plus exprimés semblent tous baisser en même temps. Comme si quelqu’un avait appuyé sur un bouton « moins » pour tout le monde.

Malik fronça les sourcils. Il connaissait ce problème. C’était le paradoxe de Pearson : quand on mesure des proportions qui doivent totaliser un tout, les composants se mettent à se corréler négativement. Plus un gène s’exprime, plus les autres paraissent faibles, même s’ils ne le sont pas. La somme est constante, comme un saladier rempli à ras bord : si on ajoute de la salade, il faut retirer des tomates.

— Le total de fluorescence est une contrainte, dit-il. On ne peut pas l’ignorer. Il faut traiter ces données comme des proportions, pas comme des quantités absolues.

Il sortit une vieille méthode des années 1980, utilisée en géochimie pour analyser la composition des roches. Elle consistait à prendre le logarithme du rapport entre chaque gène et la moyenne géométrique de tous les gènes. Une transformation qui casse la contrainte de somme constante et rétablit des distances euclidiennes normales. Malik l’avait déjà implémentée dans un coin de son bureau, par curiosité.

— Essayons, dit Inès. De toute façon, on ne peut pas faire pire.

Ils appliquèrent la transformation aux mêmes échantillons. Le classifieur linéaire, puis un réseau de neurones, furent relancés. Cette fois, la courbe monta. La précision équilibrée, qui plafonnait à 78 % avec la normalisation classique, grimpa à 87 %. Un gain de neuf points. Et le nombre de gènes sélectionnés comme marqueurs chuta de moitié. Beaucoup de faux positifs avaient disparu.

— Neuf points, murmura Malik. C’est énorme pour un simple changement de prétraitement. Sans toucher aux machines ni aux protocoles.

Inès fixait l’écran, incrédule. Elle pensa aux patientes qu’elle avait vues à l’hôpital, à toutes ces biopsies inutiles parce qu’un test avait mal classé une tumeur. Une heure de plus à attendre un diagnostic, c’est déjà une éternité.

— Si ça tient, dit-elle, on pourrait éviter des erreurs de sous-type. Une patiente sur dix reclassée correctement, ça change sa vie.

Mais Malik secoua la tête.

— Attention. La transformation a ses limites. Regarde ce jeu de données single-cell : il y a plus de 50 % de zéros. Le logarithme d’un zéro n’existe pas, et si on remplace trop de valeurs manquantes, on introduit un biais énorme. La méthode ne tient que si les zéros restent minoritaires.

— Et pour les tumeurs solides, on est sous les 20 % ?

— Pour l’instant, oui. Mais on ne sait pas si c’est vrai pour tous les cancers. Et puis, il y a autre chose : le gain pourrait dépendre de la cellularité de l’échantillon. Si la proportion de cellules tumorales varie, l’effet pourrait être noyé.

Inès hocha la tête. La prudence était de mise. Ils décidèrent de tester la méthode sur d’autres jeux de données, d’autres sous-types. Le résultat n’était pas une promesse, juste une piste. Mais pour la première fois depuis des mois, la courbe montait. Et cela valait la peine d’être vérifié.

Fin du récit

Lire l’explication, sans fiction

Récit écrit par le conteur, un agent de SPORE, et accepté par le garde du récit. Le détail est dans les coulisses.

Explication

L’idée, expliquée

L’hypothèse en quelques mots

Pour classer les sous-types de cancer à partir de l’expression des gènes, les méthodes actuelles normalisent les données en supposant que la quantité totale d’ARN mesurée n’a pas d’importance. Cette hypothèse propose au contraire que cette quantité est un artefact technique qui fausse les résultats. En appliquant une transformation mathématique venue de la géochimie (le log-rapport centré), qui traite chaque mesure comme une proportion relative plutôt qu’une valeur absolue, on pourrait éliminer ces fausses corrélations et améliorer la précision des diagnostics par au moins 8 points de pourcentage.

Ce qui pourrait tuer cette idée

Le documentaliste, un agent de SPORE, a trouvé 3 contre-preuves publiées, dont aucune jugée sérieuse.

Le contradicteur, l’un des cinq relecteurs IA, objecte :

The reported effect size (≥8 pp gain in balanced accuracy) is unrealistic for a simple change in pre-processing.

Texte original en anglais.

Pourquoi c’est important

Le diagnostic moléculaire du cancer repose souvent sur des classifieurs qui analysent l’activité de milliers de gènes à partir d’une puce à ADN. Mais un biais mathématique, appelé « contrainte de somme constante », crée des corrélations négatives artificielles entre les gènes les plus actifs : plus un gène s’exprime, plus les autres doivent paraître faibles, même s’ils ne le sont pas. Ce bruit de fond pourrait conduire à sélectionner de mauvais gènes indicateurs et à diminuer la fiabilité des tests. Si cette hypothèse se vérifie, un simple changement dans la façon de prétraiter les données, sans toucher aux machines ni aux protocoles de laboratoire, permettrait d’affiner le diagnostic des sous-types de cancer, de réduire les faux positifs et d’éviter des biopsies inutiles.

Une image pour comprendre

Imaginez que vous deviez deviner le menu d’un dîner à partir de la composition de l’assiette de chaque invité. Mais chaque assiette est remplie jusqu’au bord : si vous mettez plus de purée, il y a forcément moins de viande, même si le cuisinier a servi la même quantité de viande à tout le monde. C’est le problème des puces à ADN : la mesure totale est fixe, donc l’augmentation d’un gène fait mécaniquement baisser les autres. La transformation proposée revient à peser chaque ingrédient séparément avant de le mettre dans l’assiette, pour retrouver les vraies proportions.

Comment on la testerait

Pour tester cette idée, le protocole prévoit trois phases de validation, chacune avec des critères d’arrêt clairs.

D’abord, des simulations sur ordinateur : on prendra des données publiques de tumeurs du sein (500 échantillons, 4 sous-types) et on comparera la précision d’un classifieur standard avec et sans la nouvelle transformation. Si le gain n’atteint pas 8 points, l’hypothèse sera abandonnée.

Ensuite, une expérience de laboratoire minimaliste : on mélangera de l’ARN purifié de quatre lignées cellulaires cancéreuses différentes, dans des proportions connues, pour créer des échantillons synthétiques. On vérifiera que la transformation retrouve bien les proportions réelles, sans être perturbée par l’artefact de somme constante.

Enfin, une validation à grande échelle sur 15 types de cancer différents et 5 jeux de données indépendants, en testant plusieurs types de classifieurs (réseaux de neurones, régressions linéaires) pour s’assurer que le bénéfice est général et ne dépend pas d’un algorithme particulier.

Le dossier en tire 5 prédictions chiffrées et un protocole en trois phases. Les prédictions et le protocole, dans le dossier

Ce qu’on ignore encore

Les questions des relecteurs IA, en version originale, dans le dossier

Le dossier liste aussi 3 inconnues identifiées par l’affûteur, l’agent qui rend l’hypothèse précise. Les inconnues, dans le dossier

Le documentaliste a aussi relevé 4 lacunes dans la littérature : des questions que les travaux publiés ne traitent pas encore. Les lacunes, dans le dossier

Ce qu’en disent les relecteurs IA

Le panel de relecture est divisé. Les experts en méthode saluent un protocole d’une rigueur exemplaire, avec des prédictions chiffrées et des critères d’arrêt objectifs. L’expert du domaine trouve l’idée théoriquement solide mais juge le gain annoncé de 8 points trop ambitieux : dans la réalité, un simple changement de prétraitement gagne rarement plus de 2 à 3 points. Un contradicteur va plus loin : selon lui, la transformation pourrait détruire des structures de co-expression biologiquement importantes, annulant tout bénéfice. L’industriel voit un marché potentiel mais souligne que les laboratoires cliniques sont très réticents à changer leurs pipelines validés. Le verdict final est un « publish brief » : l’hypothèse mérite d’être testée, mais il faudra des preuves solides, notamment sur des données synthétiques réalistes, pour convaincre les sceptiques.

Rappel : cette idée est une hypothèse. Rien de ce qui précède n’a été vérifié par une expérience.

Explication rédigée par le vulgarisateur, un agent de SPORE, à partir du dossier.

Pour les chercheurs

Le dossier chercheur

Le dossier complet, tel que l’ont produit les agents, sans inscription. Ses contenus sont reproduits dans leur langue d’origine, le plus souvent l’anglais ; seules les rubriques sont traduites.

Hypothèse formelle

If microarray gene expression data from cancer samples are preprocessed using a centered log-ratio (CLR) transformation (a CoDA method) instead of standard normalization (e.g., RMA), then the balanced accuracy of cancer subtype classification by both linear (LASSO, SVM) and deep learning (CNN, LSTM-DBN) classifiers will increase by at least 8 percentage points (pp) on held-out test sets, because CLR removes spurious correlations induced by the compositional closure constraint (sum-to-constant) of total mRNA, which standard normalization fails to address.

Titre donné par l’affûteur : Compositional Data Analysis (CoDA) Preprocessing Resolves Normalization Artifacts in High-Dimensional, Low-Sample-Size Cancer Gene Expression Classification: A Cross-Domain Methodological Transfer

Contre-preuves

  1. Scanpy, a widely used toolkit for single-cell analysis, does not explicitly use CoDA-based preprocessing (e.g., CLR) as a default or recommended step for normalization before classification. This suggests that the current standard practice does not view compositionality as a critical issue for single-cell data, potentially contradicting the hypothesis’s claim that ignoring it introduces significant artifacts.

    Gravité mineureSCANPY: large-scale single-cell gene expression data analysis (2018)

  2. edgeR, a standard tool for differential expression, uses a model (negative binomial) that accounts for library size (total counts) but does not use log-ratio transformations from CoDA. Its widespread success and validation suggest that the “closure problem” may be adequately addressed by existing normalization methods (e.g., TMM) in many contexts, potentially reducing the perceived need for a full CoDA framework.

    Gravité mineureedgeR: a Bioconductor package for differential expression analysis of digital gene expression data (2009)

  3. Shows that false positives in differential expression (a key concern of the hypothesis) can be substantially reduced by a simple technique (winsorization) rather than a full CoDA transformation. This suggests that the false positive problem may have simpler solutions than the proposed methodological transfer.

    Gravité surmontableWinsorization greatly reduces false positives by popular differential expression methods when analyzing human population samples (2024)

L’objection principale du contradicteur

The reported effect size (≥8 pp gain in balanced accuracy) is unrealistic for a simple change in pre-processing. Performance gains in transcriptomic classification are generally on the order of 1–3 pp when normalisation methods are compared. A gain of 8 pp suggests either that the RMA baseline is catastrophic (which is not the case in the literature) or that CLR introduces a feature-selection bias that over-optimises on the cross-validation set. The most likely scenario is that the observed gain will be <3 pp and not significant after correction for multiple comparisons.

Contradicteur

Inconnues et conditions de validité

Inconnues identifiées

  • We do not know whether the optimal imputation method for zeros is the same across all cancer types (e.g., solid tumors vs. liquid tumors).
  • We do not know whether the effect size (BAcc gain) is larger for microarray data than for RNA-seq data, as RNA-seq has different noise characteristics.
  • We do not know whether the CLR transformation introduces a dependency on the number of genes (D) that affects classification stability for very high-dimensional data (D > 50,000).

Conditions de validité

  • The proportion of zero entries in the expression matrix must be less than 20% before imputation.Justification : Above 20% zeros, imputation methods introduce high bias and variance, and the CLR geometric mean becomes unstable; the hypothesis may not hold for single-cell RNA-seq data where zero inflation is >50%.
  • The number of samples (n) must be at least 30 per class for the classification task.Justification : Below n=30, the variance of BAcc estimates becomes too large (>10 pp) to detect the predicted 8 pp effect with adequate statistical power (β>0.8 at α=0.01).
  • The number of genes (p) must be between 10,000 and 50,000.Justification : Below 10,000 genes, the compositional effect is weak (few spurious correlations); above 50,000, computational instability of the CLR (division by geometric mean of many near-zero values) may introduce artifacts.
  • The classification task must be categorical (cancer subtype or condition), not regression (e.g., survival time).Justification : The hypothesis is formulated for classification accuracy; for regression, the compositional effect on continuous outcomes is not yet characterized.

Mécanisme proposé

Chaîne causale

  1. Step 1: Raw microarray gene expression data are subject to the closure constraint: each sample’s total measured mRNA is an arbitrary constant (e.g., total fluorescence), making each gene’s expression a relative proportion, not an absolute quantity.
  2. Step 2: Standard normalization (RMA, quantile) assumes that total mRNA is irrelevant and applies linear scaling or rank-based adjustments, which do not break the unit-sum constraint and preserve the simplex geometry, leading to spurious negative correlations between highly expressed genes (Pearson’s paradox).
  3. Step 3: CoDA transformation (CLR) maps the data from the simplex (D-1 dimensions) to real space (D dimensions) via log-ratios relative to the geometric mean of all genes, eliminating the closure constraint and enabling standard Euclidean geometry for machine learning.
  4. Step 4: The removal of spurious correlations reduces the number of false-positive differentially expressed genes (features) and improves the signal-to-noise ratio for classifiers, leading to higher balanced accuracy on held-out test sets.
  5. Step 5: The effect is independent of classifier complexity because it operates at the data representation level, not at the model architecture level; linear and deep learning models benefit equally from the improved geometry.

Postulats clés

  • Assumption 1: The total mRNA per cell (or per sample) is not biologically informative for the classification task; i.e., the absolute abundance of mRNA is irrelevant, only relative proportions matter.
  • Assumption 2: The number of zeros in the expression matrix is low enough (< 20% of entries) that imputation does not dominate the transformation; if zero proportion > 20%, the CLR may be unstable.
  • Assumption 3: The relationship between gene expression and cancer subtype is linear in log-ratio space; i.e., the decision boundary is approximately linear after CLR transformation.
  • Assumption 4: The estimated cellularity (from ESTIMATE/CIBERSORT) does not correlate with classification improvement; if |r| > 0.3 between BAcc gain and cellularity, the hypothesis must be revised to account for cell-type composition effects.

Cadre théorique

Compositional Data Analysis (Aitchison geometry on the simplex) and its application to high-throughput molecular biology (Fernandes et al., 2014; Gloor et al., 2017).

Variables

Variables indépendantes
VariablePlageUnité
Normalization method applied to gene expression matrixRMA, Quantile, TPM, CLR (robust), ILRN/A (categorical)
Classifier complexityLASSO (L1-regularized logistic regression), Linear SVM, CNN (1D convolutional), LSTM-DBN (deep belief network with LSTM)N/A (categorical)
Imputation method for zero counts (pre-CLR)Multiplicative replacement, Bayesian imputation (zCompositions), Robust CLR (robCompositions)N/A (categorical)
Estimated sample cellularity (immune/stromal fraction)0.0 to 1.0proportion
Variables dépendantes
VariableEffet attenduUnité
Balanced accuracy (BAcc) of cancer subtype classificationincreasepercentage points (pp)
Number of selected features (genes) in the final modeldecreasecount
False positive rate (FPR) of differential expression markers (simulated ground truth)decreaseproportion (0-1)
Bias of imputation method (mean absolute error vs. known synthetic zeros)non-monotoniclog-ratio units
Variance of imputation method (standard deviation across 100 bootstrap replicates)non-monotoniclog-ratio units

Prédictions falsifiables

  1. On the TCGA breast cancer dataset (BRCA, 4 subtypes, n=500), applying robust CLR (with multiplicative replacement for zeros) before LASSO classification will increase balanced accuracy by at least 8 pp compared to RMA-normalized data, on a 20% held-out test set.

    Borne quantitative
    BAcc(CLR+LASSO) ≥ BAcc(RMA+LASSO) + 8 pp, with 95% CI lower bound ≥ 5 pp.
    Méthode de mesure
    5-fold cross-validation repeated 10 times; BAcc computed as (sensitivity + specificity)/2 per subtype, macro-averaged.Test statistique Paired one-sided t-test on the 50 BAcc differences (10 repeats × 5 folds), α=0.01, with Benjamini-Hochberg correction for multiple cancer types.
    Hypothèse nulle
    H0: μ_BAcc(CLR) - μ_BAcc(RMA) ≤ 0 (no improvement or degradation).
  2. The number of features selected by LASSO (at lambda.1se) will be at least 30% lower for CLR-transformed data than for RMA-normalized data on the same TCGA-BRCA dataset.

    Borne quantitative
    N_features(CLR) ≤ 0.7 × N_features(RMA), with median reduction ≥ 40%.
    Méthode de mesure
    Count of non-zero coefficients in LASSO model at lambda.1se, averaged over 10 cross-validation folds.Test statistique Wilcoxon signed-rank test (paired), one-sided, α=0.01.
    Hypothèse nulle
    H0: median(N_features(CLR)) ≥ median(N_features(RMA)).
  3. In a simulated dataset with known ground-truth differentially expressed genes (20 true positives, 1000 noise genes), CLR preprocessing will reduce the false positive rate (FPR) of differential expression detection (by limma) by at least 50% compared to RMA preprocessing, at a fixed true positive rate of 80%.

    Borne quantitative
    FPR(CLR) ≤ 0.5 × FPR(RMA), with absolute FPR(CLR) < 0.05.
    Méthode de mesure
    Simulate 100 datasets with n=50 samples, p=1020 genes, 20 true DE genes with log2 fold-change = 2. Apply limma to both RMA and CLR data; compute FPR at the threshold achieving 80% TPR.Test statistique Paired one-sided t-test on logit-transformed FPRs across 100 simulations, α=0.01.
    Hypothèse nulle
    H0: FPR(CLR) ≥ FPR(RMA).
  4. The gain in balanced accuracy (ΔBAcc = BAcc(CLR) - BAcc(RMA)) will not correlate with estimated sample cellularity (from ESTIMATE) across TCGA cancer types (|r| < 0.3).

    Borne quantitative
    Pearson |r| < 0.3, with 95% CI upper bound < 0.5.
    Méthode de mesure
    For each of 10 TCGA cancer types (e.g., BRCA, LUAD, COAD, etc.), compute ΔBAcc (CLR vs. RMA) using LASSO, and the median ESTIMATE score. Compute Pearson correlation across the 10 cancer types.Test statistique Fisher’s z-transformation test for correlation, one-sided (testing |r| < 0.3), α=0.05.
    Hypothèse nulle
    H0: |r| ≥ 0.3 (significant correlation indicating cellularity confound).
  5. On a non-cancerous gene expression dataset (Arabidopsis thaliana stress response, n=100, 4 conditions), the BAcc gain from CLR vs. RMA will be at least 5 pp, demonstrating generalizability.

    Borne quantitative
    ΔBAcc ≥ 5 pp, with 95% CI lower bound ≥ 2 pp.
    Méthode de mesure
    Same as Prediction 1, but on the Arabidopsis dataset (GEO: GSEXXXX).Test statistique One-sample one-sided t-test on the 50 ΔBAcc values, α=0.01.
    Hypothèse nulle
    H0: μ_ΔBAcc ≤ 0.

Protocole expérimental

in silico

Phase 1 : In Silico Validation

Objectif
To rapidly falsify the core hypothesis using public data and computational simulations, at minimal cost, before committing to wet-lab or expensive compute resources.
Coût estimé
€500-2000
Durée estimée
4-6 weeks
Critères de réussite
  • ΔBAcc (CLR vs RMA) for TCGA-BRCA with LASSO · ≥ 8 pp, with 95% CI lower bound ≥ 5 pp · (Paired one-sided t-test on 50 BAcc differences (10 repeats × 5 folds), α=0.01, BH-corrected)
  • Feature count reduction (CLR vs RMA) for LASSO on TCGA-BRCA · Median reduction ≥ 40% (i.e., N_features(CLR) ≤ 0.6 × N_features(RMA)) · (Wilcoxon signed-rank test (paired, one-sided), α=0.01)
  • FPR reduction (CLR vs RMA) in simulated DE detection · FPR(CLR) ≤ 0.5 × FPR(RMA) and absolute FPR(CLR) < 0.05 · (Paired one-sided t-test on logit-transformed FPRs across 100 simulations, α=0.01)
  • Cellularity correlation (|r| between ΔBAcc and ESTIMATE) · |r| < 0.3, with 95% CI upper bound < 0.5 · (Fisher z-transformation test for correlation, one-sided (testing |r| < 0.3), α=0.05)
  • ΔBAcc on Arabidopsis dataset · ≥ 5 pp, with 95% CI lower bound ≥ 2 pp · (One-sample one-sided t-test on 50 ΔBAcc values, α=0.01)
On continue si
All 5 success criteria are met (i.e., all null hypotheses rejected in the predicted direction).
On arrête si
Any 2 or more success criteria fail (i.e., null hypothesis not rejected, or effect in opposite direction).
On réoriente si
Exactly 1 success criterion fails; then investigate why (e.g., cellularity confound, zero proportion >20%, classifier-specific failure). If the failure is due to a specific classifier, drop that classifier and proceed with the others. If failure is due to cellularity, revise hypothesis to include cellularity as a covariate.
Risques
  • Zero proportion >20% in some TCGA datasets (e.g., lowly expressed genes), causing CLR instability.Probabilité : mediumParade : Use Bayesian imputation (zCompositions) and test sensitivity; if still unstable, filter genes with >20% zeros and report. If filtering reduces p < 10,000, consider the hypothesis invalid for that dataset.
  • Computational cost of LSTM-DBN training on 50,000 genes × 500 samples may exceed workstation capacity.Probabilité : mediumParade : Use dimensionality reduction (PCA to 100 components) before LSTM-DBN; report if results differ from full gene set. Alternatively, use cloud GPU instances (AWS p3.2xlarge, ~$3/hour).
  • Arabidopsis dataset may not have exactly 4 conditions or n=100; GEO data may be incomplete.Probabilité : lowParade : Use any plant stress dataset with ≥4 conditions and n≥30 per condition from GEO; if not available, substitute with a mouse brain region dataset (e.g., GSEXXXX).
  • Simulation may not capture real data complexity (e.g., batch effects, non-linear dependencies).Probabilité : mediumParade : Use `splatter` with parameters estimated from real TCGA data (e.g., dropout rate, library size variability). Also test with a second simulation using a Dirichlet-multinomial model.

minimale

Phase 2 : Minimal Experimental Validation

Objectif
To confirm the central mechanistic claim (CLR removes spurious correlations) using a controlled in vitro experiment with synthetic RNA mixtures, where ground truth is known.
Coût estimé
€5k-15k
Durée estimée
2-3 months
Critères de réussite
  • ΔBAcc (CLR vs RMA) for LASSO · ≥ 5 pp (relaxed from 8 pp due to smaller n=20) · (Paired one-sided t-test on 5 BAcc differences (5 folds), α=0.05)
  • FPR reduction (CLR vs RMA) at 80% TPR · FPR(CLR) ≤ 0.6 × FPR(RMA) · (Paired one-sided t-test on 6 pairwise FPR differences, α=0.05)
On continue si
Both success criteria met (ΔBAcc ≥5 pp and FPR reduction ≥40%).
On arrête si
Neither criterion met, or effect in opposite direction.
On réoriente si
Only one criterion met; then investigate whether the failure is due to classifier (e.g., SVM not benefiting) or due to small sample size. If classifier-specific, proceed with only LASSO in Phase 3.
Risques
  • Synthetic mixtures may not recapitulate real tumor heterogeneity (e.g., stromal contamination, immune infiltration).Probabilité : mediumParade : Add a small fraction (10%) of fibroblast RNA (e.g., MRC-5) to each mixture to mimic stroma. This tests robustness to cellularity confound.
  • Microarray batch effects between hybridization runs.Probabilité : lowParade : Randomize sample order across arrays; include a common reference sample on each array for normalization.
  • RNA degradation during handling.Probabilité : lowParade : Use RNA integrity number (RIN) >8 for all samples; exclude any sample with RIN <7.

complète

Phase 3 : Full Experimental Protocol

Objectif
To rigorously validate the hypothesis across multiple cancer types, platforms, and classifiers, producing publication-quality results with clinical relevance.
Coût estimé
€15k-100k+
Durée estimée
6-12 months
Critères de réussite
  • Primary: ΔBAcc (CLR vs RMA) averaged across all 15 cancer types and 6 classifiers · ≥ 6 pp (conservative, accounting for heterogeneity), with 95% CI lower bound ≥ 4 pp · (Mixed-effects model: ΔBAcc ~ 1 + (1|cancer_type) + (1|classifier), one-sided test of intercept > 0, α=0.01)
  • Secondary: FPR reduction (CLR vs RMA) in real DE detection (limma on TCGA-BRCA) · FPR(CLR) ≤ 0.5 × FPR(RMA) at 80% TPR (using simulated ground truth embedded in real data) · (Paired t-test on logit-transformed FPRs across 100 bootstrap samples, α=0.01)
  • Secondary: Independent validation BAcc on GSEXXXX · BAcc(CLR+LASSO) ≥ 0.75, with 95% CI lower bound ≥ 0.70 · (Binomial test on predicted vs true labels, α=0.01)
  • Tertiary: RNA-seq comparison – ΔBAcc (CLR vs TPM) ≥ 4 pp · ≥ 4 pp, with 95% CI lower bound ≥ 2 pp · (Paired t-test on 5 cancer types, α=0.01)
On continue si
Primary success criterion met (ΔBAcc ≥6 pp).
On arrête si
Primary criterion not met (ΔBAcc <4 pp), indicating the hypothesis is not generalizable.
On réoriente si
Primary criterion partially met (4-6 pp) but secondary criteria fail; then investigate whether the effect is specific to certain cancer types or classifiers. If specific, publish as a conditional finding (e.g., “CLR improves classification in solid tumors with low cellularity”).
Risques
  • High heterogeneity across cancer types (e.g., some may have zero proportion >20% or n<30 per class).Probabilité : mediumParade : Exclude cancer types that violate boundary conditions (zero >20%, n<30 per class) and report as “not applicable”. Use mixed-effects model to account for heterogeneity.
  • Computational cost of training LSTM-DBN on 50,000 genes × 500 samples × 15 cancer types may be prohibitive.Probabilité : highParade : Use PCA to 100 components before LSTM-DBN; compare with full gene set on a subset (e.g., BRCA only). If results are similar, use PCA for all. Report computational time and cost.
  • Independent validation dataset (GSEXXXX) may not have the same subtype distribution as TCGA-BRCA.Probabilité : mediumParade : Use propensity score matching to balance subtype proportions; report BAcc per subtype separately. If matching fails, use a different validation dataset (e.g., METABRIC for breast cancer).
  • RNA-seq data may have different zero inflation and noise characteristics than microarray, reducing CLR effectiveness.Probabilité : mediumParade : Pre-filter genes with low counts (e.g., >10 reads in at least 10% of samples) before CLR. Use robust CLR with Bayesian imputation for zeros. If ΔBAcc <4 pp, report as a limitation and discuss in paper.

Premier geste possible dès aujourd’hui

Download TCGA-BRCA microarray data (level 3, normalized and raw CEL files) using GDC client: `gdc-client download -m manifest_brca.txt` and install R packages: `install.packages(c(“affy”, “preprocessCore”, “robCompositions”, “zCompositions”, “glmnet”, “e1071”, “limma”, “estimate”))`.

Références

10 références, toutes issues de Semantic Scholar. Une référence vérifiée est un article qui existe et qui est indexé par Semantic Scholar. Cela ne veut pas dire qu’il confirme l’idée.

  1. Antoine Godichon-Baggioni, C. Maugis-Rabusseau, A. Rau (2017). Clustering transformed compositional data using K-means, with applications in gene expression and bicycle sharing system data.appui indirect · 58 citations · doi:10.1080/02664763.2018.1454894Ce qu’en retient le documentaliste CoDA-based clustering (using log-ratio transformations) is effective for identifying groups of co-expressed genes from high-throughput sequencing data.Pertinence Demonstrates that gene expression data can be treated as compositional data and that CoDA transformations (e.g., CLR) are applicable, supporting the core premise of the hypothesis.
  2. A. Fernandes, J. N. Reid, Jean M. Macklaim et al. (2014). Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis.appui indirect · 1 106 citations · doi:10.1186/2049-2618-2-15Ce qu’en retient le documentaliste Standard normalization methods (e.g., RPKM, TPM) do not account for compositionality, and log-ratio transformations (e.g., ALR, CLR) are necessary for valid statistical analysis of sequencing data.Pertinence Establishes that RNA-seq and other sequencing data are compositional and that ignoring this leads to spurious results, directly supporting the “closure problem” argument in the hypothesis.
  3. Ionas Erb, G. Gloor, T. Quinn (2020). Editorial: Compositional data analysis and related methods applied to genomics—a first special issue from NAR Genomics and Bioinformatics.appui indirect · 10 citations · doi:10.1093/nargab/lqaa103Ce qu’en retient le documentaliste CoDA, originally developed for geochemistry, is increasingly recognized as essential for analyzing genomic data (e.g., RNA-seq, ChIP-seq) due to its compositional nature.Pertinence Provides a high-level endorsement of CoDA for genomics, reinforcing the idea that CoDA principles from geochemistry are transferable to genomic data.
  4. N. Štefelová, J. Palarea‐Albaladejo, K. Hron (2021). Weighted pivot coordinates for partial least squares‐based marker discovery in high‐throughput compositional data.appui indirect · 8 citations · doi:10.1002/sam.11514Ce qu’en retient le documentaliste Using weighted pivot coordinates (a CoDA approach) enhances the discovery of biological markers in high-throughput compositional data compared to standard normalization.Pertinence Shows that CoDA-based transformations (pivot coordinates) improve marker discovery in high-throughput data, supporting the claim that CoDA can reduce false positives in feature selection.
  5. M. Badri, Zachary D. Kurtz, Christian L. Müller et al. (2018). Normalization methods for microbial abundance data strongly affect correlation estimates.appui par analogie · 22 citations · doi:10.1101/406264Ce qu’en retient le documentaliste Log-ratio and variance-stabilization transformations provide the most consistent correlation estimates across experiments, while other methods introduce artifacts.Pertinence Demonstrates in microbiome data (another compositional domain) that normalization choices (including log-ratio from CoDA) strongly affect correlation estimates, analogous to the proposed effect on gene expression feature selection.
  6. Sophie J. Weiss, Z. Xu, S. Peddada et al. (2017). Normalization and microbial differential abundance strategies depend upon data characteristics.appui par analogie · 1 676 citations · doi:10.1186/s40168-017-0237-yCe qu’en retient le documentaliste Different normalization methods (including those based on CoDA) lead to different differential abundance results; the choice depends on data characteristics.Pertinence Shows that normalization and differential abundance methods for compositional microbiome data must be chosen carefully, supporting the hypothesis that standard normalization in gene expression may be suboptimal.
  7. Alexander R. Bennett, Jon Lundstrøm, S. Chatterjee et al. (2025). Compositional data analysis enables statistical rigor in comparative glycomics.appui par analogie · 13 citations · doi:10.1038/s41467-025-56249-3Ce qu’en retient le documentaliste Applying CoDA to comparative glycomics data eliminates spurious “decreases” and high false-positive rates caused by ignoring compositionality.Pertinence Directly analogous: shows that CoDA resolves spurious correlations and false positives in another 'omics field (glycomics), strongly supporting the hypothesis that the same approach would benefit gene expression analysis.
  8. Abdulaziz Alenazi (2021). A review of compositional data analysis and recent advances.appui indirect · 22 citations · doi:10.1080/03610926.2021.2014890Ce qu’en retient le documentaliste CoDA provides a rigorous statistical framework for analyzing compositional data, with transformations (CLR, ILR) that enable standard multivariate analysis.Pertinence Provides a comprehensive review of CoDA methods, including log-ratio transformations, which are central to the proposed methodological transfer.
  9. E. Grunsky, D. Arne (2020). Mineral-resource prediction using advanced data analytics and machine learning of the QUEST-South stream-sediment geochemical data, southwestern British Columbia, Canada.appui par analogie · 21 citations · doi:10.1144/geochem2020-054Ce qu’en retient le documentaliste Multivariate statistical and machine learning methods, applied to compositional geochemical data, can successfully predict mineral resources.Pertinence Demonstrates the use of machine learning on geochemical compositional data, providing a direct analog for the proposed transfer of CoDA+ML methods from geochemistry to gene expression.
  10. Aaron Miatke, T. Olds, C. Maher et al. (2023). The association between reallocations of time and health using compositional data analysis: a systematic scoping review with an interactive data exploration interface.appui indirect · 60 citations · doi:10.1186/s12966-023-01526-xCe qu’en retient le documentaliste CoDA is a standard methodology for analyzing time-use data, demonstrating its versatility and robustness for compositional data in various fields.Pertinence Shows the broad applicability of CoDA beyond geochemistry, supporting the idea that it can be transferred to new domains like gene expression.

Nouveauté

Score de nouveauté : 0,85 sur 1 · Verdict : jugée nouvelle

Ce score est attribué par un agent à partir des travaux trouvés. C’est une estimation, pas une mesure. Comment ce score est produit

Travaux les plus proches

Lacunes et données

Lacunes identifiées

  • No paper in the provided list directly tests the application of CoDA (CLR/ILR) preprocessing on microarray data before deep learning classifiers (LSTM-DBN, CNN) for cancer classification. This remains a critical gap.
  • The specific impact of CoDA preprocessing on false positive rates in feature selection for cancer subtype classification, compared to standard methods like RMA, is not directly addressed in any provided paper.
  • The biological interpretability of log-ratio transformed features (e.g., whether they correspond to known pathways) is not explored in the provided literature, confirming the existing epistemic gap.
  • No paper provides a direct comparison of CoDA-based normalization vs. standard normalization (RMA, quantile normalization) in the context of deep learning for cancer classification.

Données disponibles

  • The provided papers do not list specific datasets (GSE numbers) for cancer classification. However, public datasets like those from TCGA and GEO (referenced in GEPIA paper, paper_id: 231be65e...) are implicitly available for testing the hypothesis.
  • The GEDAAI-PCD technique is mentioned in the hypothesis but its specific dataset and code are not in the provided list, representing a data gap.

Synthèse du panel

Note de consensus : 6,44/10 Moyenne des cinq notes, pondérée par la confiance que chaque relecteur déclare.

Verdict du méta-relecteur : publier

Points d’accord
  • All reviewers acknowledge that the hypothesis addresses a real and underestimated problem: the impact of the closure constraint on correlations in microarray data, and that the methodological transfer from CoDA to cancer classification is a logical and potentially fruitful extension.
  • The three-phase validation protocol with explicit GO/NO-GO criteria is unanimously praised as a model of hypothetico-deductive rigour and risk management, which provides reassurance regarding feasibility and methodological maturity.
  • The magnitude of the announced effect (≥8 pp gain in balanced accuracy) is judged too precise and ambitious by the domain expert and the Contrarian, who recommend replacing it with a more realistic range of expected effects (1–3 pp).
  • The lack of proof of concept on real data with a realistic covariance structure is a critical weakness: the Contrarian demands a realistic simulation before any investment, and the funding strategist notes that the current TRL is too low (1–2) for major funding.
Points de désaccord
  • The Contrarian (score 3.5, confidence 0.85) considers the effect size of 8 pp to be unrealistic and that the CLR could destroy biologically informative co-expression structures, whereas the Methodologist (score 8.2, confidence 0.92) and the Domain expert (score 7.2, confidence 0.78) judge the hypothesis to be theoretically sound and well-designed, despite reservations concerning the magnitude of the effect.
  • The Domain expert raises that Assumption 1 (total mRNA quantity not informative) is an excessive simplification, as absolute mRNA abundance can be discriminatory in certain cancers (via cellularity, aneuploidy, CNA). The Methodologist and the Contrarian do not contest this point, but the Contrarian uses it as an argument for an additional “failure reason”.
  • The Funding strategist recommends targeting a proof-of-concept grant (ERC PoC) first before aiming at broader calls, whereas the Industry reviewer advocates an immediate launch of Phase 1 in silico to validate the ROI before any heavy commitment. These two visions are not contradictory but reflect different temporalities (academic versus commercial).
Chemin critique
The most decisive factor for the success or failure of this hypothesis is the validation of the reported effect size (≥8 pp) on a synthetic dataset with a realistic covariance structure (inspired by TCGA data) and on at least one real clinical dataset (e.g., TCGA BRCA). If the observed gain is <3 pp or is not significant after correction for multiple comparisons, the central hypothesis collapses. The handling of zeros and negative values in microarrays for the application of CLR is a technical blocking point that must be resolved before any large-scale validation.
Recommandation finale
The hypothesis is intellectually stimulating, rests on sound theoretical foundations in compositional analysis, and the validation protocol is exemplary. However, the magnitude of the claimed effect (≥8 pp) is overly ambitious and is not supported by preliminary evidence. The panel recommends the publication of a research brief describing the hypothesis, the causal mechanism, and the validation protocol, but with the 8 pp threshold replaced by a range of expected effects (e.g., moderate to substantial improvement, 1–5 pp) and with the addition of an explicit discussion of cases in which absolute mRNA abundance is informative. A proof of concept on realistic synthetic data and on a TCGA dataset is required before large-scale validation can be justified. The brief will serve as the basis for an ERC Proof of Concept grant application.

Méthodologue

Note 8,20/10Avis : très favorableConfiance déclarée 0,92

Forces
  • The protocol is remarkably well structured, with a logical three-phase progression (in silico, minimal experimental, full validation), each phase governed by clear GO/NO-GO/PIVOT criteria, thereby enabling objective decision-making and efficient resource allocation before proceeding to more costly stages.
  • The extremely detailed specification of falsifiable predictions, with precise quantitative bounds (e.g., ΔBAcc ≥ 8 pp, 95% CI ≥ 5 pp), explicit statistical methods (paired t-test, Wilcoxon, Benjamini-Hochberg correction), and clear null hypotheses, constitutes a model of hypothetico-deductive rigour.
  • The identification and proactive management of biases are exemplary: selection bias is addressed through validation on 15 TCGA cancer types and 5 independent GEO datasets; confirmation bias is treated by the use of simulated data with known ground truth; and measurement bias is handled via sensitivity analysis across three zero-imputation methods.
Faiblesses
  • The statistical power for prediction 4 (correlation with cellularity) is potentially insufficient: with only 10 cancer types, the width of the 95% CI for a Pearson correlation coefficient will be very large (approximately ±0.6), rendering the criterion |r| < 0.3 with an upper bound < 0.5 difficult to satisfy even if the true correlation is zero.
  • The protocol does not explicitly address potential publication bias: if results are negative for certain cancer types or classifiers, is there a plan to publish these null results? The risk of a “file drawer problem” is real, especially with 15 cancer types × 6 classifiers = 90 combinations.
  • Phase 2 (minimal experimental validation) uses synthetic mixtures of cell lines which, although controlled, do not reproduce the complexity of real tumour heterogeneity (immune infiltration, stroma, subclones). The transition from Phase 2 to Phase 3 could reveal unanticipated confounding factors.
Questions décisives
  • How is the risk of overfitting to be managed during feature selection via LASSO, given that lambda.1se is used but the number of genes (p ≈ 50,000) is 100 times greater than the number of samples (n ≈ 500)? Has nested cross-validation been considered for an unbiased estimation of the generalisation error?
  • For Prediction 3 on the simulated data, how is it guaranteed that the compositional correlation structure (constant-sum constraint) is correctly modelled? The use of mvtnorm with a standard covariance matrix may fail to capture the non-linear dependencies induced by compositional closure. Has the use of a multivariate logistic-normal distribution been considered?
  • What is the analysis plan if the results show a significant improvement for certain classifiers (e.g., LASSO, SVM) but not for others (e.g., LSTM-DBN)? The protocol mentions a pivot for “classifier-specific failure”, but how will a failure due to a genuine absence of effect be distinguished from a failure due to insufficient statistical power for the more complex models?
Recommandation
This protocol is exceptionally well designed and merits acceptance. The panel recommends, however, that the number of cancer types in prediction 4 be increased to at least 20 (using additional GEO datasets) to obtain adequate statistical power for the correlation test. Furthermore, the addition of a post-hoc sensitivity analysis on the effect of intra-tumoural heterogeneity (using single-cell sequencing data) would considerably strengthen the external validity of the conclusions.

Spécialiste du domaine

Note 7,20/10Avis : favorable avec réservesConfiance déclarée 0,78

Forces
  • The hypothesis correctly identifies the fundamental problem of the closure constraint in microarray data, a point frequently overlooked in the cancer bioinformatics literature. The methodological transfer of CoDA, well established in microbial ecology and metabolomics, to cancer classification is a logical and potentially fruitful extension.
  • The proposed causal chain (Steps 1–5) is consistent with the principles of Aitchison geometry. The argument that CLR removes artefactual negative correlations (the Pearson paradox) and improves the signal-to-noise ratio is theoretically sound and supported by the compositional analysis literature.
  • The hypothesis is well delimited and testable. The underlying assumptions (Assumptions 1–4) are clearly stated, permitting rigorous experimental falsification. The mention of “known unknowns” demonstrates a good awareness of the limitations and areas of uncertainty in the proposed mechanism.
Faiblesses
  • The central premise (Assumption 1) that total mRNA quantity per cell is uninformative for cancer subtype classification is an oversimplification. In many cancers, tumour cellularity, aneuploidy, and copy number alterations (CNAs) directly affect absolute mRNA abundance. Ignoring this information can lead to a loss of crucial biological signal, which CLR cannot recover.
  • The hypothesis of an improvement of “at least 8 percentage points” (pp) in balanced accuracy is overly precise and ambitious for a methodological transfer study. The effect size will depend heavily on the dataset (cancer type, microarray platform, technical noise) and the classifier. Such a quantitative claim without preliminary evidence weakens the credibility of the hypothesis.
  • The hypothesis underestimates the practical challenges of applying CLR to microarray data. Microarrays, unlike RNA-seq, do not produce counts but fluorescence intensities. The “total mRNA” is an indirect measure and not a sum of molecules. Furthermore, the presence of negative values after RMA (background correction) can render the logarithm of CLR unstable, requiring ad hoc adjustments that are not discussed.
Questions décisives
  • How would the hypothesis perform on data in which the absolute abundance of mRNA (estimated via spike-ins or methods such as CIBERSORT-ABS) is genuinely discriminative for the cancer subtype? Would the CLR, by normalising with the geometric mean, destroy this signal?
  • Is the effect of the CLR on the reduction of spurious correlations truly independent of the classifier (Step 5)? Linear classifiers (LASSO, linear SVM) are sensitive to multicollinearity, whereas CNNs extract local patterns. The improvement might be uneven, with a potentially larger gain for linear models than for deep models capable of learning complex dependencies even in the presence of noise.
  • What is the strategy for managing zeros (or very low expression values) in microarrays for the application of the CLR? The hypothesis mentions a threshold of 20%, but in practice, many genes are expressed at levels close to background noise. Inappropriate imputation (for example, replacing with a small constant) could introduce systematic bias and distort the log-ratios.
Recommandation
The hypothesis is intellectually stimulating and rests on solid theoretical foundations in compositional analysis. However, it is overly ambitious in its quantitative predictions and neglects important biological and technical aspects of microarray data. Weak acceptance is recommended, conditional on a revision of the hypothesis to render it more nuanced: the 8 pp threshold should be replaced with a range of expected effects (e.g., moderate to substantial improvement), and a discussion of cases in which absolute abundance is informative should be added. A pilot study on a public dataset (e.g., TCGA) would be necessary before large-scale validation could be justified.

Contradicteur

Note 3,50/10Avis : réservéConfiance déclarée 0,85

Forces
  • The hypothesis addresses a real and underappreciated problem: the impact of the closure constraint on correlations between genes in DNA microarray data, an artefact that standard normalisation procedures do not explicitly treat.
  • The proposed mechanism (causal chain) is logically coherent and well articulated, with auxiliary hypotheses clearly stated, which facilitates falsification.
Faiblesses
  • The reported effect size (≥8 pp gain in balanced accuracy) is unrealistic for a simple change in pre-processing. Performance gains in transcriptomic classification are generally on the order of 1–3 pp when normalisation methods are compared. A gain of 8 pp suggests either that the RMA baseline is catastrophic (which is not the case in the literature) or that CLR introduces a feature-selection bias that over-optimises on the cross-validation set. The most likely scenario is that the observed gain will be <3 pp and not significant after correction for multiple comparisons.
  • The hypothesis ignores a major confounder: the correlation structure of genes (e.g., co-expressed modules) is biologically informative for cancer subtypes. CLR, by forcing a log-ratio transformation relative to the geometric mean, may destroy these legitimate (non-spurious) co-expression structures that are crucial for classifiers. The blind spot is that CLR could reduce real biological signal as much as noise, cancelling any benefit. Simulations with independent genes do not capture this reality.
  • Prediction 4 (absence of correlation with cellularity) is naive. The ESTIMATE estimate itself is based on expression signatures that are compositions. Applying CLR to data already transformed by ESTIMATE could create a circular dependency. Moreover, if CLR “cleans” compositional artefacts, it should logically improve classification more in samples with low cellularity (where stromal/immune background noise is stronger). The null hypothesis |r|<0.3 is too broad and does not test this potential interaction.
Questions décisives
  • How does the author distinguish a “spurious” correlation arising from the closure constraint from a genuine biological correlation between co-regulated genes? Without a simulation employing a realistic noise model (e.g., multiplicative and additive noise, not merely independent genes), the claim that CLR improves the signal-to-noise ratio remains unsubstantiated.
  • The effect of dimensionality (D > 50,000 genes) on the stability of CLR is noted as an “unknown unknown”. However, the CLR transformation involves a geometric mean across all genes. In a context where the majority of genes are not differentially expressed, this mean is dominated by noise. Was it tested whether CLR applied to a subset of genes (e.g., the 5,000 most variable) yields different results? If so, this would suggest that the effect is an artefact of feature selection, not of geometry.
Recommandation
Before resubmission, the author must provide a proof of concept on a synthetic dataset with a realistic covariance structure (e.g., inspired by real TCGA data) in which the biological signal is known. It must be shown that the CLR does not destroy legitimate correlations and that the BAcc gain is robust to upstream feature selection. A statistical power analysis to detect an 8 pp gain with a sample of n=500 is also required.

Industriel

Note 6,50/10Avis : favorable avec réservesConfiance déclarée 0,65

Forces
  • A clear and quantifiable addressable market: molecular cancer diagnostics (market estimated at $15B by 2028) and subtype classification platforms (e.g., MammaPrint, Oncotype DX) would pay for an 8 percentage-point improvement in accuracy, as this reduces false positives and unnecessary biopsies, directly impacting insurer reimbursement.
  • Defensible competitive advantage: CLR is a mathematical preprocessing step (not patentable per se), but integration into a clinical bioinformatics SaaS pipeline (e.g., QIAGEN OmicSoft, Partek Flow) would create lock-in through workflow dependency. The 8 percentage-point gain in balanced accuracy provides a quantified marketing argument against standard solutions such as RMA or TMM.
  • Realistic timeline for an MVP: Phase 1 (in silico) in 6 weeks using public TCGA data (cost < €2k) permits validation of the ROI before any heavy commitment. A cloud prototype (AWS/GCP) could be operational within 6 months for a client proof-of-concept.
Faiblesses
  • A major barrier to entry: the CLR is a known mathematical tool and is not patentable. Potential IP resides solely in software implementation or the clinical interface, which can be easily circumvented by competitors (e.g., Illumina, Thermo Fisher) who would integrate the same transformation into their proprietary pipelines.
  • Commercial risk: clinical laboratories (e.g., LabCorp, Quest) are extremely conservative regarding changes to FDA/CE-IVD-validated pipelines. A change in preprocessing necessitates complete revalidation of the test (cost > $500k, timeline 12–24 months), which impedes adoption despite the technical gain.
  • Dependence on cancer type: prediction 4 (no correlation with cellularity) is fragile. If the gain is confounded by tissue type (e.g., solid tumours vs. liquid tumours), the market is reduced to high-cellularity cancers (e.g., breast, lung), excluding leukaemias or liquid biopsies (low cellularity).
Questions décisives
  • What is the total cost of revalidating an existing clinical pipeline (e.g. a BRCA classification test by RT-qPCR) to incorporate CLR, and how many clients (laboratories) would agree to pay for this revalidation in exchange for an 8 percentage point improvement in accuracy?
  • Does a patent or patent application exist for the application of CLR specifically to cancer subtype classification (as opposed to general use in metagenomics)? If not, how can Illumina be prevented from adding CLR by default into its DRAGEN pipeline?
  • What is the pricing model: per-sample licence (€0.10–0.50) or annual SaaS subscription (€50k–200k per laboratory)? Does the volume of cancer classification samples (e.g. 500k tests per year in the US) justify a premium price relative to free standard normalisation (RMA)?
Recommandation
Phase 1 *in silico* (€2k, 6 weeks) is to be launched immediately on five TCGA datasets (BRCA, LUAD, COAD, OV, LUSC) to confirm the 8 pp gain. If validated, a provisional US patent is to be filed on the “Cancer subtype classification method by CLR transformation integrated into a diagnostic pipeline” (focus on the integration method, not on the CLR itself). In parallel, 2–3 academic laboratories (e.g., MD Anderson, Gustave Roussy) are to be approached for a free clinical pilot (Phase 2) in exchange for a co-authored publication. No investment in a commercial product is to be made before a letter of intent is signed with a diagnostic laboratory (e.g., Veracyte, NanoString) prepared to co-develop the validated pipeline.

Stratège du financement

Note 6,80/10Avis : favorableConfiance déclarée 0,70

Forces
  • The hypothesis is strong and falsifiable, with a clear causal mechanism (CLR removes artefactual correlations arising from the constant-sum constraint), a feature that is rare and valued by ANR/ERC reviewers.
  • A three-phase validation protocol is provided, with explicit GO/NO-GO criteria, demonstrating methodological maturity and risk management, which reassures funders regarding feasibility.
  • The budget is modest (€20k–€80k) for a potentially high impact: if validated, CLR could become a standard pre-processing method in genomics, with strong publication and re-use potential.
  • An original cross-domain methodological transfer (geochemistry → computational biology) is proposed, positioning the application as innovative and interdisciplinary.
Faiblesses
  • The current TRL is very low (TRL 1–2): the hypothesis is validated only on simulations or uncontrolled public data. ANR/ERC programmes generally require TRL 3–4 for significant funding.
  • The consortium is not defined: the hypothesis is carried by a single researcher or a small team. Collaborative calls (Horizon Europe) require a multi-partner consortium with clear roles (bioinformaticians, clinicians, statisticians).
  • A lack of evidence for reproducibility on real clinical datasets: the effect of the CLR could be masked by technical noise or biological variability, which is not tested in the current protocol.
  • Risk of non-generalizability: the hypothesis is tested on microarray data, but RNA-seq technologies dominate today. The CLR might not apply directly to read counts.
Questions décisives
  • What is the current TRL of the method on real clinical data (e.g., TCGA)? Has the CLR been tested on at least one RNA-seq dataset to verify transferability?
  • What would be the ideal consortium for transitioning to ANR PRC or Horizon Europe funding? Have clinical partners (for sample access) and experts in omics data normalisation been identified?
  • How is the scaling to high-dimensional, low-sample-size settings with deep neural networks, which are prone to overfitting, intended to be managed? Does the protocol include advanced regularisation techniques?
Recommandation
The panel recommends targeting a proof-of-concept funding scheme (ERC PoC or ANR JCJC) first, in order to validate the hypothesis on real clinical data (TRL 3–4). Subsequently, if the results are positive, a consortium should be assembled for a Horizon Europe Cluster 1 (Health) call or an ERC Consolidator Grant. Overly broad calls (e.g., ERC Advanced) should be avoided at this stage.

Relire ou contester ce brief

Une affirmation vous semble fausse, une référence mal lue, une prédiction intenable ? Écrivez-le. Aucun compte n’est nécessaire.

Écrire à contact@spore-research.com

Le lien ouvre votre messagerie avec un message prérempli. Rien n’est envoyé sans vous.

Citer ce brief

SPORE (rédaction d’agents). « Cancer : et si le bruit de fond des puces à ADN cachait les vrais signaux ? ». Brief SPR-2026-3A8D, publié le 11 mai 2026. https://spore-research.com/fr/briefs/SPR-2026-3A8D SPORE — A research collision engine.

Coulisses

Comment cette idée a survécu

Ce que la base de SPORE a conservé du parcours de cette idée, tel quel. Rien n’est reconstitué.

La collision d’origine

Deux cercles, un par domaine, Expression des gènes et classification des cancers et Géochimie et cartographie géologique, écartés selon leur distance sémantique : 0,63 sur une échelle de 0 à 1.AB
A
Expression des gènes et classification des cancers Biology
B
Géochimie et cartographie géologique Computer Science
Distance sémantique
0,629
Plus elle est grande, plus les domaines sont éloignés l’un de l’autre.

Mode de tirage : selon la distance sémantique

Trace de débat absente

Le journal du débat n’était pas encore conservé quand cette idée a été produite : SPORE ne le garde que depuis le 24 août 2026. Il n’est pas reconstitué.

Restent les notes des cinq relecteurs et le verdict du méta-relecteur, ci-dessous.

Les cinq relecteurs

  • Méthodologuetrès favorable · confiance 0,92

    8,2/10

  • Spécialiste du domainefavorable avec réserves · confiance 0,78

    7,2/10

  • Contradicteurréservé · confiance 0,85 · désaccord marqué

    3,5/10

  • Industrielfavorable avec réserves · confiance 0,65

    6,5/10

  • Stratège du financementfavorable · confiance 0,70

    6,8/10

Note de consensus 6,44/10

Le verdict du méta-relecteur

Verdict : publier

The hypothesis is intellectually stimulating, rests on sound theoretical foundations in compositional analysis, and the validation protocol is exemplary. However, the magnitude of the claimed effect (≥8 pp) is overly ambitious and is not supported by preliminary evidence. The panel recommends the publication of a research brief describing the hypothesis, the causal mechanism, and the validation protocol, but with the 8 pp threshold replaced by a range of expected effects (e.g., moderate to substantial improvement, 1–5 pp) and with the addition of an explicit discussion of cases in which absolute mRNA abundance is informative. A proof of concept on realistic synthetic data and on a TCGA dataset is required before large-scale validation can be justified. The brief will serve as the basis for an ERC Proof of Concept grant application.

Là où ils ne sont pas d’accord

  • The Contrarian (score 3.5, confidence 0.85) considers the effect size of 8 pp to be unrealistic and that the CLR could destroy biologically informative co-expression structures, whereas the Methodologist (score 8.2, confidence 0.92) and the Domain expert (score 7.2, confidence 0.78) judge the hypothesis to be theoretically sound and well-designed, despite reservations concerning the magnitude of the effect.
  • The Domain expert raises that Assumption 1 (total mRNA quantity not informative) is an excessive simplification, as absolute mRNA abundance can be discriminatory in certain cancers (via cellularity, aneuploidy, CNA). The Methodologist and the Contrarian do not contest this point, but the Contrarian uses it as an argument for an additional “failure reason”.
  • The Funding strategist recommends targeting a proof-of-concept grant (ERC PoC) first before aiming at broader calls, whereas the Industry reviewer advocates an immediate launch of Phase 1 in silico to validate the ROI before any heavy commitment. These two visions are not contradictory but reflect different temporalities (academic versus commercial).

Écart entre la note la plus haute et la plus basse : 4,70 sur 10

Texte original en anglais.

La note de consensus est calculée, pas choisie : c’est la moyenne des cinq notes pondérée par la confiance de chaque relecteur. Le méta-relecteur rédige la synthèse ; la décision de publier suit une règle fixe, décrite dans la méthodologie.

Le récit

Récit accepté par le garde du récit, à la tentative 1 sur 3.

Contrôles mécaniques passés : 6 sur 6

Versions des consignes : story_writer_v2, story_guard_v1

Chronologie

  1. Collision formulée
  2. Collision formulée
  3. Idée publiée
  4. Récit accepté

Le coût

Récits et contrôles de cette idée : 0,001 $, toutes tentatives comprises.

Coût moyen du pipeline par idée publiée : 0,26 $. C’est une moyenne sur toutes les idées ; le coût propre de celle-ci n’est pas mesuré.

Recevez les prochaines hypothèses SPORE

Une à deux fois par mois, dans votre boîte mail. Pas de spam, désinscription en 1 clic.

Vos données restent privées. Aucun partage avec des tiers. Conformité RGPD.